These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 27657652

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R, Redekop WK.
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS.
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [Abstract] [Full Text] [Related]

  • 7. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P, Molik M, Foltynski P.
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N, Ko CW, Nie L, Shapiro M, Tolnay M, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.
    Clin Cancer Res; 2014 Aug 01; 20(15):3902-7. PubMed ID: 24824310
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS, Ohna A, Krivasi T.
    Appl Health Econ Health Policy; 2018 Aug 01; 16(4):569-577. PubMed ID: 29923173
    [Abstract] [Full Text] [Related]

  • 13. Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.
    Do N, Thielen FW.
    Value Health; 2023 Apr 01; 26(4):477-486. PubMed ID: 36375678
    [Abstract] [Full Text] [Related]

  • 14. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E, De la Serna-Torroba J, Escudero-Vilaplana V, Hernández-Rivas JÁ, Sánchez-Cuervo M, Sánchez-Hernández R.
    Farm Hosp; 2022 Apr 27; 46(3):121-132. PubMed ID: 36183205
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
    Casado LF, Hernández JÁ, Jarque I, Echave M, Casado MA, Castro A.
    Eur J Haematol; 2018 Mar 27; 100(3):264-272. PubMed ID: 29226472
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM, Issa DE, Pompen M, Ten Hoor G, Hogendoorn M, Joosten P, Zweegman S, Huijgens PC, Uyl-de Groot CA.
    Eur J Haematol; 2014 Mar 27; 92(5):398-406. PubMed ID: 24400940
    [Abstract] [Full Text] [Related]

  • 17. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
    Panovská A, Němcová L, Nekvindová L, Špaček M, Šimkovič M, Papajík T, Brejcha M, Lysák D, Zuchnická J, Novák J, Starostka D, Poul H, Vrbacký F, Vodárek P, Urbanová R, Plevová K, Pospíšilová Š, Mašlejová S, Brychtová Y, Koriťáková E, Smolej L, Doubek M.
    Hematol Oncol; 2020 Oct 27; 38(4):509-516. PubMed ID: 32400885
    [Abstract] [Full Text] [Related]

  • 18. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
    Casado LF, García Marco JA, Gilsanz F, González M, Ríos E, de la Serna J, Urbano A, Vicente V, Rubio-Terrés C, Castro AJ.
    Gac Sanit; 2011 Oct 27; 25(4):274-81. PubMed ID: 21664727
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.